MDT-AP-0368
Med · Medulloblastoma
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- Med
- cancer_type_detailed
- —
- subtype
- Medulloblastoma
- cancer_type
- Med
- subtype
- Medulloblastoma
- overall_survival_months
- 63.96
- os_event
- false
- age_years
- 6
- sex
- F
- new_clusters
- S2
- umap1_2d
- -1.556168609
- umap2_2d
- -9.49170146
- umap1_3d
- -3.385133461
- umap2_3d
- -1.687286596
- umap3_3d
- 5.463543608
- dataset
- Med-Taylor
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- E2F_TARGETS+0.680
- MYC_TARGETS_V1+0.650
- INTERFERON_ALPHA_RESPONSE+0.610
- G2M_CHECKPOINT+0.600
- MYC_TARGETS_V2+0.580
- MTORC1_SIGNALING+0.570
- INTERFERON_GAMMA_RESPONSE+0.520
- OXIDATIVE_PHOSPHORYLATION+0.510
- ALLOGRAFT_REJECTION+0.500
- UNFOLDED_PROTEIN_RESPONSE+0.460
Top 10 suppressed
- WNT_BETA_CATENIN_SIGNALING-0.190
- TGF_BETA_SIGNALING-0.170
- UV_RESPONSE_DN-0.130
- HEDGEHOG_SIGNALING-0.100
- HEME_METABOLISM-0.080
- KRAS_SIGNALING_DN-0.070
- MYOGENESIS-0.060
- BILE_ACID_METABOLISM-0.040
- PANCREAS_BETA_CELLS-0.020
- ANGIOGENESIS+0.020
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
9 twins match this tumor's tissue · 1 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | BS_RSRPX3S8 | Med | Medulloblastoma | 0.946 |
| 2 | SRR1313147 | — | E | 0.941 |
| 3 | SRR8942975 | — | — | 0.927 |
| 4 | BS_996ZS2A4 | ATRT | — | 0.926 |
| 5 | SRR6013600 | — | cohortA1 | 0.911 |
| 6 | SRR6013499 | — | cohortA1 | 0.910 |
| 7 | SRR6013500 | — | cohortA1 | 0.905 |
| 8 | C3F0BD22-6891-44F0-B023-02FC6EDFA7EB | — | — | 0.903 |
| 9 | SRR13311163 | — | — | 0.901 |
| 10 | f66a9fee-f63a-4398-b242-9c065bbe213d | — | — | 0.899 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 41 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| E2F_TARGETS | 0.680 | Inavolisib | — uncovered |
| MYC_TARGETS_V1 | 0.650 | Inavolisib | — uncovered |
| INTERFERON_ALPHA_RESPONSE | 0.610 | Inavolisib | — uncovered |
| G2M_CHECKPOINT | 0.600 | Inavolisib | — uncovered |
| MYC_TARGETS_V2 | 0.580 | Idelalisib | — uncovered |
| MTORC1_SIGNALING | 0.570 | Inavolisib | — uncovered |
| INTERFERON_GAMMA_RESPONSE | 0.520 | Idelalisib | — uncovered |
| OXIDATIVE_PHOSPHORYLATION | 0.510 | Remibrutinib | — uncovered |
| ALLOGRAFT_REJECTION | 0.500 | Idelalisib | — uncovered |
| UNFOLDED_PROTEIN_RESPONSE | 0.460 | Idelalisib | — uncovered |
| REACTIVE_OXYGEN_SPECIES_PATHWAY | 0.380 | Inavolisib | — uncovered |
| DNA_REPAIR | 0.350 | Idelalisib | — uncovered |
| CHOLESTEROL_HOMEOSTASIS | 0.340 | Remibrutinib | — uncovered |
| IL6_JAK_STAT3_SIGNALING | 0.340 | Inavolisib | — uncovered |
| GLYCOLYSIS | 0.330 | Inavolisib | — uncovered |
| INFLAMMATORY_RESPONSE | 0.330 | Idelalisib | — uncovered |
| UV_RESPONSE_UP | 0.320 | Idelalisib | — uncovered |
| EPITHELIAL_MESENCHYMAL_TRANSITION | 0.310 | Inavolisib | — uncovered |
| FATTY_ACID_METABOLISM | 0.290 | Inavolisib | — uncovered |
| COMPLEMENT | 0.280 | Inavolisib | — uncovered |